Pharmacokinetics of 10-hydroxycamptothecin-tetrandrine liposome complexes in rat by a simple and sensitive ultra-high performance liquid chromatography with tandem mass spectrometry.
10-hydroxycamptothecin
liposomes
pharmacokinetics
tetrandrine
Journal
Journal of separation science
ISSN: 1615-9314
Titre abrégé: J Sep Sci
Pays: Germany
ID NLM: 101088554
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
08
05
2019
revised:
08
10
2019
accepted:
30
10
2019
pubmed:
9
11
2019
medline:
30
10
2020
entrez:
9
11
2019
Statut:
ppublish
Résumé
10-Hydroxycamptothecin is a drug to cure various cancers. However, the 10-hydroxycamptothecin cannot be widely applied in clinics due to fast elimination and resistance of various cancers to the drug. Nevertheless, co-treatment with tetrandine is known to reverse the resistance of multi-drug resistant cancers, and may present an effective strategy to improve the efficacy of 10-hydroxycamptothecin. In order to improve the bioavailability and prolong the treatment time of the 10-hydroxycamptothecin in vivo, we prepared 10-hydroxycamptothecin-tetrandrine liposome complexes with 10-hydroxycamptothecin as the basic anticancer drug, tetrandrine and liposomes as carriers. In this article, an ultra-high performance liquid chromatography tandem mass spectrometry method for the analysis of 10-hydroxycamptothecin and tetrandrine in plasma has been developed, validated, and utilized to compare the pharmacokinetics of both drugs in the original dosage form and administered as liposome complexes. According to the pharmacokinetic parameters of mean residence time, half-life period and clearance rate, the 10-hydroxycamptothecin-tetrandrine liposome complexes prolongs the retention and circulation time of 10-hydroxycamptothecin in vivo, achieving a good sustained release effect. To the best of our current knowledge, the pharmacokinetic properties of 10-hydroxycamptothecin-tetrandrine liposome complexes in rats have not been reported yet. Our study can provide a helpful reference for further related study.
Identifiants
pubmed: 31701613
doi: 10.1002/jssc.201900347
doi:
Substances chimiques
Antineoplastic Agents
0
Benzylisoquinolines
0
Liposomes
0
tetrandrine
29EX23D5AJ
Camptothecin
XT3Z54Z28A
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
569-576Subventions
Organisme : Foundation for First-class Discipline of Science of Chinese Pharmacology of Jiangxi Province of China
ID : 0071
Informations de copyright
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Références
Wall, M. E., Wani, M. C., Cook, C. E., Palmer, K. H., McPhail, A. A., Sim, G. A., Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from camptotheca acuminata1,2. J. Am. Chem. Soc. 1966, 88, 3888-3890.
Li, Y. F., Zhang, R., Reversed-phase high-performance liquid chromatography method for the simultaneous quantitation of the lactone and carboxylate forms of the novel natural product anticancer agent 10-hydroxycamptothecin in biological fluids and tissues. J. Chromatogr. B 1996, 686, 257-265.
Grillet, F., Sabot, C., Anderson, R., Babjak, M., Greene, A. E., Kanazawa, A., Intramolecular isomünchnone cycloaddition approach to the antitumor agent camptothecin. Tetrahedron 2011, 67, 2579-2584.
Hsiang, Y. H., Hertzberg, R., Hecht, S., Liu, L. F., Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 1985, 260, 14873-14878.
Hsiang, Y. H., Lihou, M. G., Liu, L. F., Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 1989, 49, 5077-5082.
Yoshida, A., Ueda, T., Wano, Y., Nakamura, T., DNA damage and cell killing by camptothecin and its derivative in human leukemia HL-60 cells. Jpn. J. Cancer Res. 1993, 84, 566-573.
Hsiang, Y. H., Liu, L. F., Wall, M. E., Wani, M. C., Nicholas, A. W., Manikumar, G., Kirschenbaum, S., Silber, R., Potmesil, M., DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res. 1989, 49, 4385-4389.
Jaxel, C., Kohn, K. W., Wani, M. C., Wall, M. E., Pommier, Y., Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: Evidence for a specific receptor site and a relation to antitumor activity. Cancer Res. 1989, 49, 1465-1469.
Conover, C. D., Greenwald, R. B., Pendri, A., Shum, K. L., Camptothecin delivery systems: The utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs. Anti-Cancer Drug Des. 1999, 14, 499-506.
Fassberg, J., Stella, V. J., A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J. Phram. Sci-US. 1992, 81, 676-684.
Pantazis, P., Preclinical studies of water-insoluble camptothecin congeners: cytotoxicity, development of resistance, and combination treatments. Clib. Cancer Res. 1995, 1, 1235-1244.
Hong, M., Zhu, S., Jiang, Y., Tang, G., Pei, Y., Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin. J. Controlled Release 2009, 133, 96-102.
Zhang, L., Yang, M., Wang, Q., Li, Y., Guo, R., Jiang, X., Yang, C., Liu, B., 10-Hydroxycamptothecin loaded nanoparticles: preparation and antitumor activity in mice. J. Controlled Release 2007, 119, 153-162.
Drummond, D. C., Noble, C. O., Hayes, M. E., Park, J. W., Kirpotin, D. B., Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J. Phram. Sci-US. 2008, 97, 4696-4740.
Tedjarati, S., Baker, C. H., Apte, S., Huang, S., Wolf, J. K., Killion, J. J., Fidler, I. J., Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon α combined with paclitaxel. Clin. Cancer Res. 2002, 8, 2413-2422.
Tortora, G., Di Isernia, G., Sandomenico, C., Bianco, R., Pomatico, G., Pepe, S., Bianco, A. R., Ciardiello, F., Synergistic inhibition of growth and induction of apoptosis by 8-chloro-cAMP and paclitaxel or cisplatin in human cancer cells. Cancer Res. 1997, 57, 5107-5111.
Mo, J., Eggers, P. K., Raston, C. L., Lim, L. Y., Development and validation of a LC/TOF MS method for the determination of carboplatin and paclitaxel in nanovesicles. Anal. Bioanal. Chem. 2014, 406, 2659-2667.
Li, D., Cao, Z., Liao, X., Yang, P., Liu, L., The development of a quantitative and qualitative method based on UHPLC-QTOF MS/MS for evaluation paclitaxel-tetrandrine interaction and its application to a pharmacokinetic study. Talanta 2016, 160, 256-267.
Bhagya, N., Chandrashekar, K. R., Tetrandrine-A molecule of wide bioactivity. Phytochem. 2016, 125, 5-13.
Fu, L. W., Zhang, Y. M., Liang, Y. J., Yang, X. P., Pan, Q. C., The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenografts derived from human breast adenocarcinoma MCF-7/adr cells. Eur. J. Cancer 2002, 38, 418-426.
Fu, L., Liang, Y., Deng, L., Ding, Y., Chen, L., Ye, Y., Yang, X., Pan, Q., Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Chemoth. Pharm. 2004, 53, 349-356.
Zhang, Z., Yan, J., Xu, K., Ji, Z., Li, L., Tetrandrine reverses drug resistance in isoniazid and ethambutol dual drug-resistant Mycobacterium tuberculosis clinical isolates. Bmc. Infect. Dis. 2015, 15, 153.
Hou, Y., Guo, T., Wu, C., He, X., Effect of tetrandrine combined with epirubicin on the growth of human breast carcinoma multidrug resistance cell line. Yakugaku Zasshi 2008, 128, 663-666.
Qiu, W., Su, M., Xie, F., Ai, J., Ren, Y., Zhang, J., Guan, R., He, W., Gong, Y., Guo, Y., Tetrandrine blocks autophagic flux and induces apoptosis via energetic impairment in cancer cells. Cell Death Dis. 2014, 5, e1123.
Tao, Y., Huang, S., Yang, G., Li, W., Cai, B., A simple and sensitive LC-MS/MS approach for simultaneous quantification of six bioactive compounds in rats following oral administration of aqueous extract and ultrafine powder of Astragalus propinquus: Application to a comparative pharmacokinetic study. J. Chromatogr. B 2018, 1096, 31-38.
Zhang, Z., Li, R., Liu, S., Yin, L., Xu, T., Fawcett, J. P., Gu, J., Liquid chromatography tandem mass spectrometry with triple stage fragmentation for highly selective analysis and pharmacokinetics of alarelin in rat plasma. J. Sep. Sci. 2019, 42, 3033-3040.
Qi, X., Wang, X., Cheng, T., Wu, Q., Mi, N., Mu, X., Guo, X., Zhao, G., Huang, Z., Ye, J., Zhang, W., Comprehensive characterization of multiple components and metabolites of Xiaojin Capsule based on ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. J. Sep. Sci. 2019, 42, 2748-2761.
Guo, K., Cang, J., A novel tetrandrine-loaded chitosan microsphere: Characterization and in vivo evaluation. Drug Des. Dev. Ther. 2016, 10, 1291.
Wang, S., Ye, T., Yang, B., Yi, X., Yao, H., 7-Ethyl-10-hydroxycamptothecin proliposomes with a novel preparation method: Optimized formulation, characterization and in-vivo evaluation. Drug. Dev. Ind. Pharm. 2013, 39, 393-401.
Li, G., Cai, C., Ren, T., Tang, X., Development and application of a UPLC-MS/MS method for the pharmacokinetic study of 10-hydroxy camptothecin and hydroxyethyl starch conjugate in rats. J. Pharmaceut. Biomed. 2014, 88, 345-353.
Gu, G., Black, M., Cookson, C., Fiorella, A., Li, Y., Gorman, S. H., Bakhtiar, R., Validation of an LC-MS/MS method for simultaneous quantification of venlafaxine and its five metabolites in rat plasma and its application in a pharmacokinetic study. J. Chromatogr. B 2018, 1087, 29-35.
Song, N., Zhang, S., Li, Q., Liu, C., Establishment of a liquid chromatographic/mass spectrometry method for quantification of tetrandrine in rat plasma and its application to pharmacokinetic study. J. Pharmaceut. Biomed. 2008, 48, 974-979.
Yang, C., Guo, L., Liu, X., Zhang, H., Liu, M., Determination of tetrandrine and fangchinoline in plasma samples using hollow fiber liquid-phase microextraction combined with high-performance liquid chromatography. J. Chromatogr. A 2007, 1164, 56-64.